AbbVie Inc. (ABBV)
AbbVie (ABBV) Stock Dips While Market Gains: Key Facts
AbbVie (ABBV) closed at $182.31 in the latest trading session, marking a -2.4% move from the prior day.
AbbVie Adds More Than $24B in 6 Months: How to Play ABBV Stock
ABBV adds $24B in market cap as Skyrizi and Rinvoq drive growth post-Humira, with more upside from a strong pipeline.
Jim Cramer's Safest Stock For Retirees
Jim Cramer has a mixed record when it comes to choosing stocks.
Here's Why AbbVie (ABBV) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Will AbbVie's Growing Oncology Portfolio Aid Top-line Growth?
ABBV's growing oncology portfolio, now spanning five therapies, is helping offset Imbruvica's sales decline and boost top-line growth.
2 Dividend Aristocrats Bargains To Buy And 'Never Let Go'
Buying Dividend Aristocrats at bargain prices can be a winning investment strategy. I highlight two such names that are undervalued compared to historical norms while paying strong and well-covered dividends. Both carry moat-worthy attributes and provide economically essential products and services that make them recession resilient.
I'm Buying Dividend Giants At Huge Discounts
Now is a great time to be an income and value investor, particularly in the energy and pharmaceutical spaces. I highlight 2 undervalued names that provide well-covered dividends with a strong growth outlook. The market seems to be overly rotated on near-term headwinds while ignoring the long-term growth drivers, resulting in a dislocation between price and value.
AbbVie's migraine drug meets main goal of late-stage study
AbbVie said on Wednesday its migraine drug met the main goal and was superior to a generic drug in a head-to head late-stage trial.
Here's Why AbbVie (ABBV) Fell More Than Broader Market
In the most recent trading session, AbbVie (ABBV) closed at $185.48, indicating a -2.82% shift from the previous trading day.
AbbVie's Venclexta Misses Goal in Myelodysplastic Syndromes Study
Venclexta fails to meet survival goals in ABBV's phase III MDS study, marking another clinical setback for the cancer drug.
Is AbbVie (ABBV) a Buy as Wall Street Analysts Look Optimistic?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
